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
Fokustema
Nytt vaccin
Läs senare
Svenskt genombrott om kvarka
Det svenska medicinföretaget Intervacc har gjort vad som verkar vara ett stort genombrott: ett biverkansfritt vaccin mot den fruktade bakteriella sjukdomen kvarka.
